Navigation Links
Data for Investigational Tiotropium Show Improved Lung Function and Sustained Bronchodilation in Patients with Moderate Asthma Severity
Date:9/10/2013

rol 50 mcg

123 mL
(P < 0.0001)

106 mL
(P < 0.0001)

114 mL
(P < 0.0001)To characterize the treatment response as greater than or equal to 0.5, measured by the ACQ, treatment with tiotropium (either 2.5 mcg or 5 mcg) resulted in a statistically significant improvement in the ACQ responder rate at 24 weeks compared with placebo and comparable to that of salmeterol. ACQ responder rates, performed on the pooled MezzoTinA-asthma results, were as follows:

  • Placebo: 57.7 percent (n=299/518)
  • Tiotropium 2.5 mcg once daily: 64.5 percent (n=332/515; P = 0.03)
  • Tiotropium 5 mcg once daily: 64.3 percent (n=330/513; P = 0.03)
  • Salmeterol 50 mcg twice daily: 66.5 percent (n=356/535; P = 0.004)
  • Patients in the MezzoTinA-asthma® studies were permitted to receive additional background therapy, including antihistamines, nasal steroids and leukotriene modifiers. Long-acting beta agonists (LABAs) were not permitted during the study (salmeterol was included as an active comparator for the trial).

    Adverse events were balanced across the four treatment groups groups in the pooled analysis with 58.2 percent of patients receiving tiotropium 2.5 mcg once daily reporting an adverse event compared to 57.3 percent of patients in the tiotropium 5 mcg once daily group, 54.3 percent of patients who received salmeterol 50 mcg twice daily and 59.1 percent of patients receiving placebo. The most commonly reported adverse events* were asthma, peak expiratory flow (PEF) rate decreased, nasopharyngitis and upper respiratory tract infection.

    About the UniTinA-Asthma® Clinical Trial Program
    The MezzoTinA-asthma® studies are a part of the comprehensive Phase 3 trial program, UniTinA-asthma®, which includes a number of clinical trials in adults, adolescents and pediatric patients across dif
    '/>"/>

    SOURCE Boehringer Ingelheim
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
    2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
    3. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
    4. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
    5. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
    6. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
    7. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
    8. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
    9. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
    10. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
    11. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... Patterson Medical, formerly the medical business ... is now an independent company with today,s completion ... by Madison Dearborn Partners (MDP).  ... transition period before rebranding as the world,s leading ...  With the focused resources and expertise of MDP, ...
    (Date:8/28/2015)... KONG , August 28, 2015 ... in collaboration with one of the leading academics in ... (current world record holder in life extension for model ... insights into biology of aging and age-related diseases, primarily, around ... The work has just been published as "Stability analysis of ...
    (Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015 /PRNewswire/ ... that its shareholders have approved Mylan,s proposed acquisition ... TASE) and the related issuance of Mylan ordinary ... meeting of shareholders held today. The transaction received ... extraordinary general meeting. In addition, the transaction received ...
    Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
    ... BETHESDA, Md., May 14 Spherix Incorporated (Nasdaq: SPEX ), ... and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today ... Company Highlights , , ... Created a wholly owned subsidiary, Biospherics Incorporated, ...
    ... SAN DIEGO, May 14 TargeGen, Inc. today ... a multi-center clinical trial of TG101348, an oral, ... patients with myelofibrosis on May 7, 2009.(Logo: ... conducted at six centers in the USA. The ...
    Cached Medicine Technology:Spherix Reports First Quarter 2009 Earnings 2Spherix Reports First Quarter 2009 Earnings 3Spherix Reports First Quarter 2009 Earnings 4Spherix Reports First Quarter 2009 Earnings 5Spherix Reports First Quarter 2009 Earnings 6Spherix Reports First Quarter 2009 Earnings 7
    (Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... to have beneficial effects as sleep aids and calming remedies, which help to improve ... the result of a great deal of research in the field of regenerative medicine ...
    (Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Kathleen Kall has been promoted from Administrative assistant to Executive Assistant ... communication, you’ll interact with a proven professional, focused on your goals. Kathleen ...
    (Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
    (Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
    (Date:8/29/2015)... , ... August 29, 2015 , ... Dr. Tim Novelli, ... His mission is to increase acceptance of the chiropractic field in the military. ... further debilitate them. Although Chiropractic was made available to the VA program over ...
    Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
    ... checking the profits and safety of the drugs the ... monitor that only branded and quality medicines are sold ... Pharmaceutical Price Regulation Scheme [PPRS] is a voluntary organization ... and quality of the drugs every 5 years. It ...
    ... to bare metal stents, placement of stents that ... the artery re-narrowing nine months following angioplasty for ... an article in the September 14 issue of ... of atherosclerotic coronary artery disease, according to background ...
    ... up with a disaster-planning guide to help the people ... tropical storms, hurricanes, tidal waves and cyclones. ,No ... vulnerable to some sort of natural disaster such as ... terrorist attacks are also possible. Both natural disasters and ...
    ... findings of a recent study researchers say that certain chemicals ... to help current and former smokers ward off development of ... ,Researchers say their study provides significant insight into ... which the process can be slowed down after exposure has ...
    ... over the increasing malfunction of heart devices, which they ... and 2002. ,The Food and Drug Administration (FDA) ... and heart-device manufacturers recently, which found that 4,225 defibrillators ... defibrillators failed in the previous 10 years, reports online ...
    ... Mammography is used for early detection of breast cancer and ... year and self examination of the breasts for lumps every ... of cancer is necessary to start an early treatment which ... reported in the New England Journal of Medicine has shown ...
    Cached Medicine News:Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Stents That Release Medication To Check Artery Narrowing 2Health News:Disaster Planning Guide From Harvard Health Publications 2Health News:Scientists Concerned Over Increasing Malfunction Of Heart Devices 2Health News:Digital Mammogram For Detection Of Breast Cancer In Women With Dense Breasts 2
    ... 6 is an enzyme immunoassay (EIA) test ... various specific nuclear antigens (SS-A, SS-B, RNP/Sm, ... is used as an aid in the ... connective tissue disease (MCTD), Sjgren's syndrome and ...
    The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
    The PalmSAT® 2500 series are small, yet versatile digital pulse oximeters for accurate assessment of blood oxygen saturation and pulse rate. Choose alarm or non-alarm versions for your portable ...
    The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
    Medicine Products: